CHM — Chimeric Therapeutics Share Price
0.000.00%
Last trade - 00:00- AU$13.79m
- AU$12.90m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.94 | ||
| Price to Tang. Book | 9.53 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -69.07% | ||
| Return on Equity | -75.85% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 30th Jun | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Chimeric Therapeutics Limited is an Australia-based clinical-stage cell therapy company. The Company is focused on the discovery, development, and commercialization of cell therapies for patients with cancer. Its pipeline includes CHM 1101 and CHM 2101. Its CHM 1101 (CLTX CAR-T) is a CAR-T therapy developed for the treatment of patients with solid tumors. CHM-1101 is being studied in a Phase 1B clinical trial in recurrent/ progressive glioblastoma. CHM 2101 is a third generation CDH17 CAR T, which is in preclinical development with a planned Phase I clinical trial in neuroendocrine tumors, colorectal, pancreatic and gastric cancer. Its pipeline also includes the CORE-NK platform, a clinically validated, off-the-shelf natural killer (NK) cell therapy platform to their portfolio (CHM 0201). The Company is also focused on the development of NK and CAR NK assets with plans for Phase 1B clinical trials in solid tumors and blood cancers.
Directors
- Paul Hopper CHM
- Phillip Hains SEC
- Cynthia Elkins DRC
- George Matcham DRC (68)
- Leslie Chong NED
- Lesley Russell NED (55)
- Last Annual
- June 30th, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- February 2nd, 2020
- Public Since
- January 18th, 2021
- No. of Shareholders
- 3,635
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Australian Stock Exchange - SEATS
- Shares in Issue
- 725,840,586
- Address
- Level 3, 62 Lygon Street, Carlton, MELBOURNE, 3053
- Web
- https://chimerictherapeutics.com/
- Phone
- +61 398245254
- Auditors
- Grant Thornton Audit Pty Ltd
Upcoming Events for CHM
Chimeric Therapeutics Ltd Annual Shareholders Meeting
Similar to CHM
Actinogen Medical
Australian Stock Exchange - SEATS
Adalta
Australian Stock Exchange - SEATS
Algorae Pharmaceuticals
Australian Stock Exchange - SEATS
Alterity Therapeutics
Australian Stock Exchange - SEATS
Amplia Therapeutics
Australian Stock Exchange - SEATS
FAQ
What is the Chimeric Therapeutics share price?
As of Today at 13:57 UTC, shares in Chimeric Therapeutics are trading at AU$0.02. This share price information is delayed by 15 minutes.
How has the Chimeric Therapeutics share price performed this year?
Shares in Chimeric Therapeutics last closed at AU$0.02 and the price had moved by -55% over the past 365 days. In terms of relative price strength the Chimeric Therapeutics share price has underperformed the ASX All Ordinaries Index by -59.01% over the past year.
What are the analyst and broker recommendations for Chimeric Therapeutics?
There is no consensus recommendation for this security.
What is the Chimeric Therapeutics dividend yield?
Chimeric Therapeutics does not currently pay a dividend.
Does Chimeric Therapeutics pay a dividend?
Chimeric Therapeutics does not currently pay a dividend.
When does Chimeric Therapeutics next pay dividends?
Chimeric Therapeutics does not currently pay a dividend.
How do I buy Chimeric Therapeutics shares?
To buy shares in Chimeric Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Chimeric Therapeutics?
As of the previous close price of AU$0.02, shares in Chimeric Therapeutics had a market capitalisation of AU$13.07m.
Where are Chimeric Therapeutics shares listed?
Here are the trading details for Chimeric Therapeutics:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: CHM
What kind of share is Chimeric Therapeutics?
Based on an overall assessment of its quality, value and momentum Chimeric Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Chimeric Therapeutics share price forecast for 2024?
The analyst consensus target price for shares in Chimeric Therapeutics is AU$0.60. That is 3233.33% above the last closing price of AU$0.02.
Analysts covering Chimeric Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -AU$0.05 for the next financial year.
What is the trend in the Chimeric Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Chimeric Therapeutics. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -39.32%.
As of the last closing price of AU$0.02, shares in Chimeric Therapeutics were trading -35.39% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Chimeric Therapeutics PE Ratio?
The Chimeric Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.02.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Chimeric Therapeutics?
Chimeric Therapeutics' management team is headed by:
- Paul Hopper - CHM
- Phillip Hains - SEC
- Cynthia Elkins - DRC
- George Matcham - DRC
- Leslie Chong - NED
- Lesley Russell - NED